Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ENTPD3 | O75355 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.55 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32661844 | 0.97 | RXFP1 (0.60) | RXFP1KDM4EMEN1CYP1A2CYP2D6 | |
| SCHEMBL32662391 | 0.92 | RXFP1 (0.60) | RXFP1CA1CA2CA4CA9 | |
| SCHEMBL32661821 | 0.92 | KDM4E (0.63) | RXFP1KDM4EMEN1CYP1A2CYP2D6 | |
| SCHEMBL32661691 | 0.85 | LARS1 (0.57) | RXFP1CA1CA2CA4CA9 | |
| SCHEMBL12546109 | 0.82 | RXFP1 (0.60) | RXFP1CA1CA2CA4CA9 | |
| SCHEMBL32662244 | 0.82 | P2RX3 (0.70) | RXFP1 | |
| SCHEMBL1800042 | 0.82 | ATG7 (0.63) | RXFP1CA1CA2CA4CA9 | |
| SCHEMBL1796966 | 0.82 | ATG7 (0.63) | RXFP1CA1CA2CA4CA9 | |
| SCHEMBL5321913 | 0.82 | ATG7 (0.63) | RXFP1CA1CA2CA4CA9 | |
| SCHEMBL32661839 | 0.81 | SLC29A1 (0.74) | RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015592-A1 | NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2026-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015592-A1 | NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF | NAE1, NEDD8, UBA3 | RXFP1 4444/4885KDM4E 686/4885MEN1 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.